Crispr Theraptc (NASDAQ:CRSP) - Equities research analysts at Oppenheimer Holdings issued their Q2 2017 earnings per share estimates for Crispr Theraptc in a report released on Monday. Oppenheimer Holdings analyst L. Cann expects that the company will post earnings of ($0.62) per share for the quarter. Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Crispr Theraptc’s Q3 2017 earnings at ($0.48) EPS, Q4 2017 earnings at ($0.77) EPS, FY2017 earnings at ($2.42) EPS, Q1 2018 earnings at ($0.68) EPS, Q2 2018 earnings at ($0.81) EPS, Q3 2018 earnings at ($0.62) EPS, Q4 2018 earnings at ($1.00) EPS, FY2018 earnings at ($3.11) EPS, FY2019 earnings at ($2.73) EPS, FY2020 earnings at ($4.34) EPS and FY2021 earnings at ($5.36) EPS.
A number of other equities analysts have also commented on CRSP. Chardan Capital initiated coverage on shares of Crispr Theraptc in a report on Monday, March 27th. They set a “buy” rating and a $23.50 price target on the stock. Cann initiated coverage on shares of Crispr Theraptc in a report on Monday. They set a “market perform” rating on the stock. Finally, SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a report on Thursday, July 13th. They set a “hold” rating and a $16.00 price target on the stock. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $21.92.
ILLEGAL ACTIVITY NOTICE: This story was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://stocknewstimes.com/2017/07/31/crispr-theraptc-expected-to-post-q2-2017-earnings-of-0-62-per-share-nasdaqcrsp-updated.html.
Crispr Theraptc (NASDAQ:CRSP) opened at 16.53 on Thursday. The stock has a 50 day moving average price of $15.69 and a 200-day moving average price of $17.92. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00. The firm’s market cap is $661.15 million.
Crispr Theraptc (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.70 million for the quarter.
Institutional investors have recently added to or reduced their stakes in the stock. Wellington Management Group LLP raised its position in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Credit Suisse AG purchased a new position in Crispr Theraptc during the first quarter valued at about $1,742,000. Paulson & CO. Inc. purchased a new position in Crispr Theraptc during the first quarter valued at about $1,099,000. Monashee Investment Management LLC raised its position in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. Finally, IHT Wealth Management LLC purchased a new position in Crispr Theraptc during the first quarter valued at about $110,000. Institutional investors and hedge funds own 24.07% of the company’s stock.
In other news, insider Samarth Kulkarni sold 11,615 shares of Crispr Theraptc stock in a transaction on Tuesday, April 25th. The shares were sold at an average price of $16.78, for a total transaction of $194,899.70. Following the transaction, the insider now owns 137,047 shares in the company, valued at $2,299,648.66. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock in a transaction on Friday, July 14th. The stock was sold at an average price of $16.84, for a total transaction of $1,176,425.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 451,845 shares of company stock worth $7,454,471. 39.98% of the stock is owned by company insiders.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.
